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Introduction: The cystic ﬁbrosis-related diabetes (CFRD) guidelines produced by the UK CF Trust differ from those used in Europe and the US.
We conducted a study to establish current practice.
Method: Paediatric and adult questionnaires were devised and emailed to the 48 specialist UK CF centres.
Results: Completed questionnaires were returned by 39/48 (81%) centres. Only 3/21 (14%) paediatric centres begin annual screening at 12 years
(as per UK guidelines), 11/21 (52%) start to screen at 10 years (as per European and US guidelines) and 5/21 (24%) begin screening at a child's
ﬁrst annual review. The oral glucose tolerance test is used as a screening test in 33/39 (85%) of centres but only 3/33 (9%) use it in isolation. Home
glucose monitoring is the most frequently used diagnostic test undertaken in 32/39 (82%) centres, and again this is rarely used in isolation. The
decision to initiate insulin is often shared between specialist nurses and doctors.
Conclusions: In the UK the majority of CF centres use the OGTT to screen and HGM to diagnose CFRD. The use of other tools varies with poor
adherence to UK guidelines. These 2004 guidelines would beneﬁt from being updated to reﬂect current best evidence.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Cystic ﬁbrosis-related diabetes1. Introduction
Cystic fibrosis-related diabetes (CFRD) is unusual in children
under the age of 10 years. After this age there is an age related
increase in the prevalence of CFRD of 5% per year. By the age
of 20 years, 24% of CF adults have CFRD [1,2]. It has a major
detrimental impact on pulmonary function, nutrition and survival
in CF [3–5]. These effects are frequently seen prior to the diagnosis
of CFRD being made [6–8]. This highlights the importance of
screening to ensure a prompt diagnosis and minimise the⁎ Corresponding author at: Academic Department of Child Health, University
Hospital of North Staffordshire, Newcastle Road, Stoke-on-Trent ST4 6QG, UK
Tel.: +44 1782 675289.
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http://dx.doi.org/10.1016/j.jcf.2014.01.008.lished‘pre-diabetic’ effects. In 2004 the United Kingdom (UK) CF Trust
developed guidelines regarding CFRD screening, diagnosis and
management [9]. However, these guidelines differ from those used
in Europe (2005) and the United States (US) (2010) [10,11]. The
differences are summarised in Table 1. We therefore conducted
a study to establish current UK clinical practice and determine
adherence to the UK CF Trust CFRD guidelines.
2. Methods
Two questionnaires were devised with input from senior CF
clinicians, a senior diabetic clinician, a specialist CF nurse and a
specialist CFRD nurse. Both collected data on the screening and
diagnosis of CFRD, as well as the personnel involved. The first
questionnaire was designed specifically for adult CF centres and
the second for paediatric CF centres. The relevant questionnaireby Elsevier B.V. All rights reserved.
Table 1
Differences between national CFRD guidelines.
UK CF Trust guideline [9] European consensus statement [10] US CFF Clinical Care Guidelines [11]
Annual screening to
commence at
12 years 10 years 10 years
Screening tool OGTT OGTT OGTT
Diagnostic tool(s) OGTT and HGM OGTT OGTT & classic symptoms or OGTT & 2nd
confirmatory test (FPG, A1C or 2nd OGTT)
Decision to start treatment HGM & clinical status Blood glucose profiles & clinical status All patients with diagnosis of CFRD
UK: United Kingdom, US: United States, CF: cystic fibrosis, CFF: Cystic Fibrosis Foundation, OGTT: oral glucose tolerance test, HGM: home glucose monitoring,
FPG: fasting plasma glucose, and A1C: glycosylated haemoglobin.
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centres (24 paediatric and 24 adult). Up to 2 follow-up e-mails
were sent if responses were not received.
3. Results
3.1. Response rate
Completed questionnaires were returned by 39/48 centres
(81%); 18 adult and 21 paediatric.
3.2. Screening
Only 3/21 (14%) paediatric centres begin annual CFRD
screening at 12 years (as per the UK CF Trust guidelines), 11/21
(52%) start at 10 years (as per European and American guidelines)
[9–11] and 5 begin at the child's first annual review. See Fig. 1.
The most common test used for the annual CFRD screen is the
oral glucose tolerance test (OGTT), used in 33/39 (85%) centres.
However, this is only used in isolation by 3/33 (9%) centres.
Results are usually combined with random plasma glucose
(RPG) and/or glycosylated haemoglobin (HbA1C) measure-
ments. Nineteen of 33 centres only measure the blood glucose
at 2 h, 13measure it at 1 and 2 h and one centre measures it at 30,
60, 90 and 120 min. Continuous glucose monitoring systems5%
24%
5%
52%
14%
Fig. 1. Percentage of paediatric centres starting C(CGMSs) are used as the annual screening tool for CFRD in 5/18
(28%) adult centres, but only one centre uses this tool in isolation.
Home glucose monitoring (HGM) is used as a screening tool in 4/
18 (22%) adult centres. In comparison, only 2/21 (10%) paediatric
centres use CGMSs or HGM for CFRD screening. In centres that
screen from the first annual review, RBGorHbA1C is used initially
and then when the child is older OGTT or CGMS is used. The
majority of adult and paediatric centres undertake additional CFRD
screening between annual reviews if the patient has symptoms of
hyperglycaemia deterioration in respiratory function, before
surgery, during corticosteroid use and prior to starting enteral
feeds. This assessment was more likely to be undertaken if the
patient was known to have impaired glucose tolerance. Most
centres used HGM to undertake this assessment.
3.3. Diagnosis
The test most frequently used to diagnose CFRD is HGM,
undertaken by 17/18 (94%) adult centres and 15/21 (71%)
paediatric centres. This is usually combined with HbA1C and/or
CGMSs. CGMS is undertaken for diagnostic purposes in 23/39
(59%) centres. In paediatric centres, diagnostic tests are more
commonly undertaken in isolation. Of the 9 centres, which use
HGM alone for CFRD diagnosis, 6 (67%) are paediatric and of
the 5 centres, which used CGMSs alone, 4 (80%) are paediatric.Variable dependent on the
childs clinical condition*
First annual review
2 years
10 years
12 years
Age at which CFRD Screening 
Programmes Start in Paediatric 
Centres
*This centre did not begin screening at a specific age. 
The team undertook a screening test only when they 
believed that CFRD was probable such as when they 
noted unexplained deterioration in lung function 
measurements.
FRD screening programmes at different ages.
591K.L. Wickens-Mitchell et al. / Journal of Cystic Fibrosis 13 (2014) 589–5923.4. Management
The decision to initiate insulin is usually shared between a CF
consultant and a consultant diabetologist. However, in 4/39 (10%)
centres, a nurse has sole responsibility and in 2/39 (5%) a CF
consultant has sole responsibility. The location in which patients
are seen for their CFRD management varies and patients may
attend more than one type of clinic. The most common location is
at a combined CF/CFRD clinic which occurs at 22/39 (56%)
centres. In 9/39 (23%) centres patients are seen in a general diabetic
clinic and in 5 (56%) of these this is the only clinic in which they
are seen for their CFRD.
4. Discussion
This study has demonstrated that the UK clinical practice
for the screening and diagnosis of CFRD is not uniform. Specialist
CF centres use various methods and there is poor adherence to CF
Trust guidelines. However, clinical practice on the screening and
diagnosis of CFRD has changed since the UK CF Trust guidelines
on CFRD were published in 2004 and they would benefit from
being updated to reflect the current best available evidence.
The UK CF Trust guidelines recommend that annual
CFRD screening should begin at aged 12 years but only 3/21
paediatric CF centres do this. The evidence to support earlier
screening includes a reported prevalence of CFRD in patients
aged 10–19 years of 17–26% [4,12]. Improvement in clinical
parameters is also seen when children of this age with CFRD
are treated with insulin [13]. Evidence supporting even earlier
screening includes a study which found that 42% of 6 year olds
developed CFRD within 5 years if they had impaired glucose
tolerance (2 h glucose = 7.8–11.1 mmol/L) or indeterminate
glucose tolerance (glucose N 11.1 at 1 h and b7.8 mmol/L at
2 h) on an OGTT [14].
Themajority (85%) of CF centres use the OGTT as a screening
tool in keeping with all the CFRD guidelines but there is wide
variation in how it is used. It enables individuals to be categorised
into distinct groups of glucose tolerance which is helpful for
assessment and management but the cut-offs used are derived
from a non-CF population and have not been validated in CF. The
sensitivity and specificity of the OGTT have also been questioned
as results can vary over time [15]. It has also failed to identify
patients with hyperglycaemia within the diabetic range whose
weight and lung function improved with insulin [16]. Twelve of
the 33 centres in the UK which use the OGTT take additional
glucose measurements to the 2 (0 and 120 min) recommended in
the UK CF Trust guidelines. This is supported by studies showing
that an elevated glucose at 60 min which reverts to normal by
120 min (indeterminate glucose tolerance) is associated with
worse pulmonary function and body mass index [7].
Since the UK CF Trust CFRD guidelines were produced in
2004 the use of CGMSs has become more widespread. These
devices produce individual blood glucose profiles and can identify
hyperglycaemic episodes not evident on OGTT [17,18]. Less
blood glucose levels are needed when compared to home glucose
monitoring. The disadvantages of CGMSs include their cost and
the time to complete and interpret profiles. Some studies have alsoshown a significant difference between the CGMSs and plasma
glucose readings [19].
The variation inwhich a professional clinicianmakes the CFRD
management decisions and where the patient is reviewed for
CFRD care is dependent on the available expertise and facilities at
each centre. Providing the clinic environmentmeets the appropriate
standards of care and professionals have the necessary experience
and training, many different models may reach the expected
standard. However, if patients are being seen outside their usual CF
clinic the same strict infection control measures must be practised
as occur in a CF clinic.
In summary this study demonstrates wide variation in the UK
clinical practice regarding the screening, diagnosis and treatment
of CFRD. Some of this variation in practice relates to a relative
lack of evidence that will only be improved by large, high quality
studies. In addition, the current UK CF Trust CFRD guidelines
would benefit from being updated to include the best current
available evidence. This addition of evidence is especially relevant
to the newer investigations such as CGMSs.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2014.01.008.References
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